Stock comparison
Haemonetics
STERIS
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
STE
STERIS
Market cap
$21.26B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | STE | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 53C | HAE |
| Benjamin Graham | 85A | 68B | HAE |
| Philip Fisher | 60C | 58C | HAE |
| Peter Lynch | 54C | 52C | HAE |
| Joel Greenblatt | 31F | 35D | STE |
| Charlie Munger | 54D | 42D | HAE |
| Terry Smith | 55D | 48D | HAE |
Side-by-side metrics
| Metric | HAE | STE |
|---|---|---|
| Market cap | $2.98B | $21.26B |
| P/E (TTM) | 24.8x | 25.3x |
| EV/EBIT | 14.1x | 17.7x |
| ROIC (TTM) | 8.37% | 8.51% |
| Gross margin | 55.74% | 44.25% |
| Net margin | 7.29% | 13.18% |
| Revenue CAGR 5y | 7.65% | 8.88% |
| EPS CAGR 5y | 24.62% | 33.45% |
| Debt / Equity | 1.5x | 0.0x |
| Dividend yield | 0.0% | 1.22% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Gross margin55.74%vs 44.25%+21%
- EV/EBIT14.1xvs 17.7x+20%
STE leads on
- Dividend yield1.22%vs 0.0%+100%
- Debt / Equity0.0xvs 1.5x+99%
- Market cap$21.26Bvs $2.98B+86%
- Net margin13.18%vs 7.29%+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.